Important update: The molecule discussed in ADA 2026 abstract 2839-LB is identified as VRX-0075, a preclinical candidate. Researcher Jonathan Douros described VRX-0075 as a Volari Therapeutics asset. Several abstract authors disclosed current research support from Eli Lilly, but the disclosure alone does not establish that Lilly funded this particular study. Public evidence does not establish VRX-0075 as a Lilly-owned clinical pipeline medicine. The public sources reviewed for this article do not report a human trial or an approved use. VRX-0075 should not be confused with retatrutide.
Research update, November 8, 2026: Added a comparison of the two distinct quintuple-agonist strategies, clarified the limits of the reported findings, and refreshed dated development-status wording.
Five-receptor designs offer a broader signaling profile to investigate, but receptor count alone cannot establish that a candidate is useful or safe.
At the American Diabetes Association’s 86th Scientific Sessions in June 2026, researchers presented a long-acting peptide designed to activate five receptor systems in one molecule: the GLP-1, GIP, glucagon, amylin, and calcitonin receptors. The candidate, VRX-0075, produced greater weight loss than retatrutide in obese rats when the compounds were compared at the same molar dose.
That result is scientifically interesting. It is not evidence that VRX-0075 will outperform retatrutide in people. For a separate four-receptor candidate also studied against retatrutide in rats, see our CT-G32 vs retatrutide research overview. The compounds and studies are distinct.
The distinction matters because retatrutide now has a large human development program and positive Phase 3 results, while the publicly available VRX-0075 evidence consists of a conference abstract describing laboratory and animal findings. No human safety, tolerability, dose-escalation, or efficacy data have been reported for VRX-0075. Even its relationship to Lilly needs careful wording: several authors disclosed current Lilly research support, while a researcher identified VRX-0075 and VRX-0136 as Volari Therapeutics lead assets. The disclosure does not specify whether Lilly supported this particular work.
Interest in five-receptor research centers on whether simultaneous signaling can be balanced and reproduced independently. An animal comparison is hypothesis-generating, not evidence of clinical superiority.
This guide explains what VRX-0075 is, what abstract 2839-LB actually reported, how each of its five receptor targets may contribute, why receptor balance matters more than receptor count, and where the candidate fits beside retatrutide and Lilly’s broader obesity pipeline.
Key Takeaways
- VRX-0075 is a long-acting, preclinical quintuple agonist designed to activate GLP-1, GIP, glucagon, amylin, and calcitonin receptors.
- “2839-LB” is the ADA 2026 late-breaking abstract number, not the molecule’s name.
- The abstract identifies VRX-0075 as a development candidate; some authors disclose current Lilly research support. A researcher separately identified it as a Volari Therapeutics asset.
- In obese rats, VRX-0075 produced significantly greater weight loss than retatrutide at the same molar dose.
- The molecule showed in-vitro potency comparable with retatrutide at GLP-1, GIP, and glucagon receptors and with cagrilintide at amylin and calcitonin receptors.
- The researchers reported a rat half-life about 50% longer than semaglutide and suggested that the pharmacokinetic profile could support weekly dosing in humans.
- The public sources reviewed do not report human trials or human safety data. Rat results cannot establish superiority over retatrutide in clinical care.
- Five receptor targets are not automatically better than three. Potency ratios, signaling behavior, exposure, tissue distribution, titration, and tolerability may matter more than the receptor count.
What Is the “Eli Lilly Quintuple Agonist”?
The phrase “Eli Lilly quintuple agonist” is a useful search term but an imprecise scientific label.
The compound behind the recent headlines is VRX-0075. It is a single engineered peptide intended to activate five receptor systems:
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
- Amylin receptors
- Calcitonin receptor
The late-breaking abstract was presented as 2839-LB: “A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats.”
The authors described VRX-0075 as a development candidate. Disclosures listed current research support from Eli Lilly for several investigators, while public comments from the lead author described VRX-0075 and VRX-0136 as Volari Therapeutics assets. Until a licensing agreement, acquisition, pipeline listing, or company announcement says otherwise, the most accurate description is:
VRX-0075 is a preclinical quintuple agonist identified by a researcher as a Volari Therapeutics asset. Some authors disclosed current Lilly research support.
The author disclosures do not by themselves establish Lilly ownership or funding for this specific study.
VRX-0075 is not approved by the FDA or any other regulator. It is not a commercial medicine, and the public record reviewed for this article does not show a registered human clinical trial. “GLP-5” is sometimes used informally online, but it is not a formal drug class and there is no “GLP-5 receptor.”
What Is 2839-LB?
2839-LB is the abstract identifier assigned to the late-breaking ADA 2026 presentation. It is not a chemical code, generic name, or brand name.
This distinction corrects one of the biggest weaknesses in early coverage. Before the abstract became available, some articles treated “2839-LB” as though it might be the compound’s development code. The published abstract identifies the candidate as VRX-0075.
The ADA 2026 abstract appeared in Diabetes, volume 75, supplement 1, with DOI 10.2337/db26-2839-LB. Conference abstracts are valuable because they disclose new findings quickly, but they contain far less methodological detail than a full peer-reviewed paper. Important questions—including group sizes, exact doses, study duration, body-composition results, food-intake data, statistical methods, and organ-specific safety findings—cannot be answered from the short abstract alone.
Two Different Meanings of “Quintuple Agonist”: VRX-0075 vs GLP-1/GIP-Lanifibranor
Same target count, different pharmacology. Two separate research approaches are being discussed as quintuple agonists. Their molecular designs, receptor combinations and evidence must be kept separate. “GLP-5” is too vague to identify which compound or study someone means.
On smaller screens, scroll the comparison table sideways.
| Feature | VRX-0075 | GLP-1/GIP-Lanifibranor |
|---|---|---|
| Five targets | GLP-1R, GIPR, glucagon receptor, amylin receptors, calcitonin receptor | GLP-1R, GIPR, PPARα, PPARγ, PPARδ |
| Molecular design | Engineered peptide with five-target activity | Incretin peptide chemically linked to the small molecule lanifibranor |
| Published evidence | ADA 2026 abstract 2839-LB: laboratory and obese-rat findings | Full Nature paper: laboratory and mouse experiments |
| Key comparators | Retatrutide in obese rats | Semaglutide and the experimental GLP-1/GIP backbone, MAR709, in mice |
Primary reports: VRX-0075 ADA abstract and Nature study of GLP-1/GIP-lanifibranor.
What makes the lanifibranor approach different?
The incretin component acts as both a signal and a delivery vehicle. Binding to GLP-1 or GIP receptors helps bring the linked compound into receptor-expressing cells. Its lanifibranor component engages PPARs, nuclear receptors involved in regulating metabolic genes. This is the basis of the “Trojan horse” description: the research tests where an additional drug acts, as well as which targets it engages. Helmholtz Munich explains the delivery concept.
What does “6,900-fold lower dose” actually mean?
The Nature authors compared the conjugate’s lanifibranor molar payload with a previously used standalone lanifibranor dose in animal research. Their approximately 6,900-fold figure is a dose comparison, not a measure of receptor activation, weight-loss superiority or human safety. It does not establish a human dose.
Keep the comparisons and limitations attached to the right compound
The Nature study does not establish a head-to-head victory over tirzepatide. Its experimental dual backbone was MAR709. Nor does it establish muscle preservation: diet-induced obese mice lost slightly more lean mass than with the dual backbone, while lean mass did not differ from semaglutide. Lean mass is not a muscle-specific measurement.
Reassuring findings on selected safety measurements in mice do not prove freedom from side effects. Helmholtz explicitly notes that translation to humans remains unresolved, including differences between mouse and human GIP receptors.
Evidence boundary: The sources reviewed for this update do not establish human efficacy for either quintuple construct or a direct comparison between them. Human research on standalone lanifibranor does not establish the performance of the linked molecule. A five-target label is a starting point for understanding the research, not a ranking of compounds.
How Obesity Drug Research Moved From One Receptor to Five
The move toward multi-agonists is not simply a contest to collect receptor targets. It reflects the biology of body-weight regulation.
Body weight is influenced by communication among the brain, gastrointestinal tract, pancreas, liver, adipose tissue, skeletal muscle, and autonomic nervous system. Hormones released during and after a meal affect appetite, meal termination, gastric emptying, insulin secretion, glucagon release, nutrient storage, and energy expenditure. A drug acting on one pathway can produce meaningful benefits, but it also encounters biological counter-regulation and dose-limiting side effects.
The modern progression is often summarized this way:
| Therapy or candidate | Main receptor targets | Evidence status reviewed November 8, 2026 |
|---|---|---|
| Semaglutide | GLP-1 | Approved for obesity and type 2 diabetes under different brands |
| Tirzepatide | GIP + GLP-1 | Approved for obesity and type 2 diabetes under different brands |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational; positive Phase 3 results reported |
| VRX-0075 | GLP-1 + GIP + glucagon + amylin + calcitonin | Preclinical; rat and in-vitro findings reported at ADA 2026 |
This table should not be read as a simple ladder in which every additional receptor guarantees more weight loss. Semaglutide, tirzepatide, retatrutide, and VRX-0075 differ in far more than target count. Their potency at each receptor, pharmacokinetics, molecular architecture, dose escalation, and safety margins can produce very different clinical profiles.
The GLP-1 Receptor: Appetite, Glucose Control, and a Proven Foundation
GLP-1, or glucagon-like peptide-1, is released from intestinal L cells after nutrient intake. Its receptor is expressed in several tissues involved in metabolic regulation, including pancreatic and central nervous system pathways.
Pharmacologic GLP-1 receptor activation can enhance glucose-dependent insulin secretion, reduce inappropriate glucagon secretion in some contexts, slow gastric emptying—particularly early in treatment—and reduce food intake through central satiety pathways. The “glucose-dependent” aspect is important: insulinotropic activity rises when glucose is elevated, which helps distinguish the mechanism from therapies that stimulate insulin regardless of glucose level.
GLP-1 receptor agonism forms the clinical foundation of semaglutide and contributes to tirzepatide and retatrutide. It also provides a logical backbone for a five-receptor design because it can counterbalance some of the glucose-raising effects associated with glucagon receptor activation.
Still, GLP-1 activity is not a frictionless appetite switch. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and treatment discontinuation can occur. Gastric-emptying effects may change with continued exposure, and individual response varies. Increasing GLP-1 potency indefinitely would not necessarily improve study outcomes if adverse effects limit dose escalation or continuation in clinical trials.
For VRX-0075, the abstract reports in-vitro GLP-1 receptor potency comparable with retatrutide. That is a laboratory comparison, not proof that the two drugs would produce equivalent GLP-1 effects at clinically tolerable human doses.
The GIP Receptor: More Than a Secondary Incretin
GIP, or glucose-dependent insulinotropic polypeptide, is another nutrient-responsive incretin hormone. It is released primarily from K cells in the upper small intestine and can enhance insulin secretion when glucose is elevated.
For years, GIP was viewed skeptically as an obesity-drug target because people with type 2 diabetes can have an impaired insulin response to native GIP, and because some preclinical findings raised questions about fat storage. Tirzepatide changed the practical conversation. Its clinical success demonstrated that combining GIP and GLP-1 receptor agonism can generate substantial glucose and weight effects, even though the precise contribution of GIP remains an active area of investigation.
GIP receptor activation may influence insulin secretion, adipose-tissue nutrient handling, central nervous system pathways, and tolerability. Some hypotheses propose that GIP activity can complement GLP-1 signaling or allow a different balance of efficacy and gastrointestinal effects. These explanations should not be presented as settled fact; human pharmacology is more complex than assigning one outcome to each receptor.
In a multi-agonist, GIP potency must be considered relative to GLP-1 and glucagon potency. A molecule with strong GIP activity and modest glucagon activity could behave differently from one with the reverse profile, even if both are advertised as triple agonists.
VRX-0075 reportedly matched retatrutide’s in-vitro potency at GIP receptors. Again, potency in a receptor assay does not reveal the complete in-vivo effect. Drug exposure, receptor expression, signaling bias, and species differences all matter.
The Glucagon Receptor: Potential Energy Expenditure With a Glucose Trade-Off
Glucagon is often reduced to the phrase “burns more calories,” but that description leaves out the central pharmacologic challenge.
The glucagon receptor is highly relevant to hepatic metabolism. Glucagon signaling can increase hepatic glucose production, promote lipid oxidation, influence amino-acid metabolism, and contribute to energy expenditure. Those properties make glucagon receptor agonism attractive in an obesity drug, particularly when combined with incretin activity that supports glucose control.
The same pathway can also raise blood glucose. Too much glucagon activity, or the wrong balance relative to GLP-1 and GIP activity, could undermine glycemic control or introduce other safety and tolerability concerns. Successful co-agonist design therefore depends on calibrated activity rather than maximal stimulation.
Retatrutide is a leading clinical test of this triple-agonist concept. It activates GIP, GLP-1, and glucagon receptors in one molecule. The published TRIUMPH-1 Phase 3 report describes 25.0% mean weight reduction at 80 weeks with 12 mg retatrutide versus 3.9% with placebo in adults with obesity without diabetes, using the treatment-regimen analysis. Results must be identified by trial, population, dose and statistical approach; headline percentages from different analyses are not interchangeable. Our retatrutide Phase 3 research overview provides broader context. None of these human results establishes how VRX-0075 would perform in humans.
VRX-0075 reportedly has glucagon-receptor potency comparable with retatrutide in vitro. The scientific idea is to preserve a retatrutide-like incretin/glucagon core while adding amylin and calcitonin-family activity. Whether that design improves human efficacy without worsening adverse effects is unknown.
The Amylin Receptors: A Complementary Satiety System
Amylin is a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells. It contributes to meal termination, slows gastric emptying, suppresses post-meal glucagon release, and acts in central pathways involved in satiation and food intake.
Amylin biology is especially relevant because it is complementary to, but not identical with, GLP-1 biology. Combining the two systems may strengthen satiety through partially distinct neural circuits. This is one reason amylin analogues and GLP-1/amylin combinations have become a major focus across the obesity-drug industry.
The receptor terminology requires care. An amylin receptor is not simply one standalone protein labeled “AMYR.” Functional amylin receptors are complexes formed when the calcitonin receptor associates with receptor activity-modifying proteins, or RAMPs. Different RAMP combinations create amylin receptor subtypes with different pharmacologic characteristics.
That architecture explains why amylin and calcitonin activity can overlap and why candidate drugs are described as selective amylin agonists, nonselective amylin analogues, or dual amylin and calcitonin receptor agonists. It also means that counting “amylin” and “calcitonin” as two entirely independent pathways can oversimplify the receptor biology.
The VRX-0075 abstract reports amylin-receptor potency comparable with cagrilintide. Cagrilintide is a long-acting amylin analogue with activity across calcitonin-family receptor systems and has been studied alone and with semaglutide. Matching its in-vitro potency does not establish equal efficacy or tolerability, but it clarifies the design goal: add a cagrilintide-like satiety component to a retatrutide-like triple-agonist component in one peptide.
The Calcitonin Receptor: Closely Intertwined With Amylin Signaling
Calcitonin is best known for its role in calcium and bone physiology, but calcitonin-family receptors are also involved in appetite and energy-balance research. The calcitonin receptor can signal on its own and can combine with RAMP proteins to form amylin receptor subtypes.
This is why statements such as “the drug activates amylin plus calcitonin” need context. The targets are pharmacologically distinguishable, but they are members of an interconnected receptor system rather than two unrelated switches.
Dual amylin and calcitonin receptor agonists have reduced food intake and body weight in preclinical studies. Cagrilintide itself has measurable activity across this receptor family. At the same time, researchers continue to investigate whether broader calcitonin-receptor activation adds efficacy, changes nausea or aversion pathways, affects bone biology, or creates other long-term trade-offs.
For VRX-0075, the published abstract reports calcitonin-receptor potency comparable with cagrilintide and no observable toxicology findings in a non-regulatory setting. “No observable toxicology findings” must be interpreted narrowly. It does not mean the candidate has completed formal toxicology studies, and it cannot predict long-term human safety.
Why Amylin Has Become One of the Hottest Areas in Obesity Research
GLP-1 medicines proved that pharmacologic satiety signaling can produce clinically meaningful weight reduction. Amylin offers another route into the appetite-control network.
Several features explain the interest:
- Amylin acts in hindbrain and related central pathways involved in meal termination.
- Its mechanism overlaps with GLP-1 in some outcomes but is not identical.
- Long-acting analogues can make a naturally short-lived hormone more practical as a drug.
- Combining amylin and incretin activity may produce additive or synergistic effects.
- Different amylin-receptor selectivity profiles may create opportunities to optimize efficacy and tolerability.
Lilly’s own pipeline includes eloralintide, a selective amylin-receptor agonist in clinical development. Novo Nordisk has studied cagrilintide with semaglutide and is developing amycretin, a GLP-1/amylin co-agonist. Xcel’s cagrilintide versus eloralintide comparison explains how selective and broader calcitonin-family approaches differ. Other companies are developing selective and nonselective amylin strategies. This competitive activity supports the broad scientific thesis behind VRX-0075 even though it does not validate this particular molecule.
The next decisive questions are not whether amylin can influence body weight—it can—but which receptor profile, dose, delivery format, and combination strategy produces the best long-term balance of fat loss, tolerability, function, and adherence.
Receptor Balance Matters More Than Receptor Count
“Quintuple agonist” is a powerful headline. It is not a complete pharmacologic description.
Two molecules can activate the same five receptor families and behave very differently. Consider a simplified example. One candidate might be highly potent at GLP-1 and amylin receptors but only weakly active at glucagon receptors. Another might have stronger glucagon activity and less amylin activity. Both qualify as quintuple agonists, but their effects on appetite, glucose, heart rate, energy expenditure, nausea, and dose escalation could diverge substantially.
Researchers must evaluate:
- Relative potency: How strongly does the molecule activate each receptor?
- Intrinsic efficacy: Does it produce full or partial signaling at each target?
- Signaling bias: Does it favor certain intracellular pathways over others?
- Pharmacokinetics: How long does it circulate, and how stable is exposure?
- Tissue distribution: Which organs and neural regions see meaningful concentrations?
- Receptor occupancy: How much target engagement occurs at a tolerable dose?
- Species translation: Do rodent receptor pharmacology and exposure predict human responses?
- Titration: Can an effective study dose be reached without unacceptable adverse effects?
The VRX-0075 abstract provides a useful starting point. It says potency at GLP-1, GIP, and glucagon receptors was comparable with retatrutide, while potency at amylin and calcitonin receptors matched cagrilintide. That suggests a deliberate attempt to combine two validated pharmacologic profiles.
But “comparable potency” is not the same as a complete potency table, and it does not show how simultaneous activation behaves in living humans. More receptors can create synergy; they can also create competing effects or a narrower therapeutic window.
VRX-0075 vs Retatrutide
Retatrutide is the obvious benchmark because VRX-0075 appears designed to retain the same three core receptor activities and add amylin/calcitonin-family signaling.
| Feature | Retatrutide | VRX-0075 |
|---|---|---|
| Developer | Eli Lilly and Company | Volari Therapeutics, according to researcher; some authors disclosed current Lilly research support |
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | Yes | Yes |
| Amylin receptors | No direct agonism described | Yes |
| Calcitonin receptor | No direct agonism described | Yes |
| Evidence level | Large human clinical program with positive Phase 3 results | In-vitro and obese-rat data reported in an ADA 2026 abstract |
| Dosing concept | Once weekly in clinical trials | Preclinical pharmacokinetics proposed as compatible with weekly human dosing |
| Human efficacy | Reported across Phase 2 and Phase 3 studies | Unknown |
| Human safety and tolerability | Characterized in clinical trials; gastrointestinal effects and discontinuations reported | Unknown |
| Regulatory status | Investigational, not approved as of November 8, 2026 | Preclinical, not approved |
The rat comparison used the same molar dose, which is more informative than comparing arbitrary milligram doses across molecules with different molecular weights. Even so, equal molar dosing does not prove equal human exposure, receptor occupancy, or tolerability.
Retatrutide’s strongest advantage is not receptor count; it is evidence maturity. Thousands of participants have contributed human data across its clinical program. VRX-0075’s advantage is theoretical breadth supported by an encouraging preclinical signal.
Calling VRX-0075 “stronger than retatrutide” is therefore premature. The accurate conclusion is that it produced greater weight loss in one reported obese-rat comparison.
What the Preclinical Evidence Actually Showed
A frequently misread number: The ADA abstract mentions weight loss exceeding 30% in its background discussion of bariatric surgery. It does not report that percentage as a VRX-0075 result. The abstract reports greater rat weight loss than retatrutide, without giving the numerical weight-loss percentage.
What makes the five-target claim interesting? Receptor-count headlines are easy to remember but do not reveal each receptor’s actual potency, exposure or contribution to experimental outcomes. Even a compelling comparison in rats cannot establish how VRX-0075 would perform in a controlled human study. For the nearest relevant clinical-stage benchmark, see retatrutide Phase 3 findings; for other multi-target programs still at different research stages, explore the Weight Loss Atlas clinical pipeline.
The ADA 2026 abstract reported four main findings:
- VRX-0075 activated GLP-1, GIP, glucagon, amylin, and calcitonin receptors.
- Its in-vitro potency was comparable with retatrutide at the first three receptors.
- Its in-vitro potency was comparable with cagrilintide at amylin and calcitonin receptors.
- In obese rats, it produced significantly greater weight loss than retatrutide at the same molar dose.
The researchers also reported a half-life in obese rats approximately 50% longer than semaglutide and stated that this profile suggested suitability for weekly dosing in humans. That is a projection, not a human dosing result.
The phrase “no observable toxicology findings in a non-regulatory setting” offers limited reassurance. Non-regulatory exploratory assessments help teams decide whether to invest in formal development, but they are not substitutes for good laboratory practice toxicology, repeat-dose studies in multiple species, reproductive toxicology, carcinogenicity assessment where required, or clinical safety monitoring.
The abstract does not provide enough information to determine whether the extra weight loss came primarily from lower food intake, higher energy expenditure, fluid shifts, altered lean mass, or a combination of effects. A full paper or poster dataset would be needed to evaluate body composition, caloric intake, indirect calorimetry, organ weights, clinical chemistry, and histopathology.
Why Rat Results Often Do Not Translate Directly to Humans
Rodent obesity models are essential for screening metabolic candidates. They allow controlled diets, repeated body-composition measurements, tissue sampling, and comparisons that would be impractical in early human research.
They also have clear limitations:
- Receptor sequence, expression, and pharmacology differ by species.
- Rodents have different energy expenditure and thermoregulation.
- Dose exposure can scale unpredictably between rats and humans.
- Food-intake suppression in a controlled cage environment does not capture human behavior.
- Nausea and malaise are difficult to measure directly in species that cannot vomit.
- Short animal studies may miss chronic safety findings.
- Large weight changes can include different proportions of fat and lean tissue.
Many candidates look exceptional in rodents and fail because human efficacy is weaker, adverse effects limit dosing, manufacturing is difficult, or the commercial formulation cannot maintain the desired exposure.
The proper interpretation is neither dismissal nor hype. Greater weight loss than retatrutide in obese rats is a credible reason to continue development. It is not a forecast of a specific percentage of human weight loss.
Potential Advantages—and the Questions Attached to Each
If the pharmacology translates, VRX-0075 could offer several theoretical advantages.
Broader satiety signaling. Adding amylin-receptor activity may reduce meal size through pathways that complement GLP-1. The unanswered question is whether the combination increases useful satiety without excessive nausea, aversion, or loss of appetite.
Greater total weight reduction. The rat data support this hypothesis. Human trials would need to show that any difference is clinically meaningful and not simply the result of greater intolerance.
A single-molecule design. One peptide can provide synchronized exposure across five targets, potentially simplifying administration compared with two separate injections. The trade-off is less flexibility: clinicians cannot independently adjust the incretin and amylin components.
Weekly dosing potential. The reported half-life suggests a long-acting profile. Human pharmacokinetic studies must confirm the dose interval and accumulation pattern.
Metabolic effects beyond the scale. GLP-1, GIP, glucagon, and amylin pathways can affect glucose control, liver metabolism, and other cardiometabolic measures. None of these benefits has yet been demonstrated for VRX-0075 in humans.
Possible Risks and Development Challenges
The most obvious risk is gastrointestinal intolerance. GLP-1-based agents commonly produce nausea, vomiting, diarrhea, constipation, and abdominal symptoms, especially during escalation. Amylin and calcitonin-family agonism can also influence gastric emptying, appetite, and hindbrain pathways. Combining them could improve efficacy, amplify intolerance, or do both.
Other questions include:
- Can glucagon activity be balanced without worsening hyperglycemia?
- Will heart rate or other cardiovascular measures change?
- Does rapid weight loss disproportionately reduce lean mass?
- Could calcitonin-receptor activity have clinically relevant long-term effects outside appetite pathways?
- Will five-target pharmacology create a narrow dosing window?
- Can the peptide be manufactured consistently at commercial scale?
- Will anti-drug antibodies or injection-site reactions emerge?
- Can participants stay on treatment long enough to realize the predicted benefit?
Safety cannot be inferred by adding the known profiles of retatrutide and cagrilintide. A unimolecular construct can have its own distribution, metabolism, impurities, immunogenicity, and off-target behavior.
Lean Mass, Bone, and Functional Outcomes
Future obesity drugs will increasingly be judged by what is lost, not only how much is lost.
Meaningful weight reduction typically includes both fat mass and lean tissue. Some lean-mass change reflects water and organ tissue, but skeletal-muscle preservation is especially important for older adults, people with frailty risk, and anyone losing weight rapidly. Bone health and physical function also matter during long-term treatment.
The VRX-0075 abstract does not report body-composition outcomes. It therefore cannot support claims that the drug preserves muscle or preferentially removes fat. Calcitonin-receptor activity should not be assumed to protect bone without direct evidence.
Human development should examine dual-energy X-ray absorptiometry or other body-composition measures, strength, physical function, dietary intake, and outcomes in older adults. Resistance exercise and adequate protein remain relevant supportive strategies in clinical obesity care, but they are not substitutes for drug-specific evidence.
Where VRX-0075 Fits Beside Lilly’s Obesity Pipeline
VRX-0075 should not be inserted into Lilly’s official pipeline as though it were a confirmed company program. It is better understood beside that pipeline.
Lilly’s publicly discussed obesity portfolio includes:
- Tirzepatide: an approved dual GIP/GLP-1 receptor agonist marketed for obesity and type 2 diabetes under different brands.
- Retatrutide: an investigational GIP/GLP-1/glucagon triple agonist with positive Phase 3 results reported in 2026.
- Orforglipron: an oral, nonpeptide GLP-1 receptor agonist. The FDA approved the prescription product Foundayo in April 2026 for specified weight-management indications; see the FDA announcement. This approval does not extend to separate research materials.
- Eloralintide: an investigational selective amylin-receptor agonist being studied in obesity and related conditions.
- Additional combination and indication-expansion programs: Lilly continues to evaluate obesity medicines across cardiometabolic and obesity-related diseases.
VRX-0075 complements these themes: retatrutide supplies the triple-agonist benchmark, while eloralintide demonstrates Lilly’s strategic interest in amylin biology. The authors’ disclosures do not establish that Lilly funded this specific work or will license or acquire VRX-0075.
Another investigational compound, brenipatide, illustrates research into the GIP and GLP-1 pathways in a different setting, including a registered study of alcohol use disorder.
The broader next-generation obesity drug pipeline may compete on several dimensions at once: peak efficacy, oral convenience, less frequent dosing, better tolerability, lean-mass preservation, disease-specific outcomes, and personalization.
Could a Quintuple Agonist Replace Retatrutide?
Not on the available evidence.
Retatrutide is years ahead in development and has human efficacy and safety data. VRX-0075 has a promising preclinical profile but must still pass candidate selection, manufacturing, formal toxicology, regulatory review, first-in-human testing, dose escalation, proof-of-concept trials, and large confirmatory studies.
Even if VRX-0075 eventually produces greater average weight loss in clinical studies, different compounds and formulations may be studied for different outcomes. Oral formulations, amylin-selective agents and approaches to maintenance each raise distinct research questions. Their relative value depends on evidence from appropriately designed trials.
The future is unlikely to be one universal “strongest” obesity medicine. Other candidates, including the triple agonist UBT251, illustrate how crowded and mechanistically diverse this research landscape has become. It is more likely to be a portfolio of therapies differentiated by efficacy, risk, route, comorbidities, and individual response.
What Happens Next?
The next meaningful milestones would include:
- A full preclinical publication with dose-response, body-composition, food-intake, energy-expenditure, and safety data.
- Formal toxicology and manufacturing work supporting an investigational new drug application.
- Registration of a first-in-human trial.
- Phase 1 data describing pharmacokinetics, tolerability, dose escalation, and early weight effects.
- Clear disclosure of ownership, licensing, or partnership arrangements.
Until then, confident timelines for human trials or approval are speculation.
Frequently Asked Questions
What is the Eli Lilly quintuple agonist?
The phrase usually refers to VRX-0075, a preclinical peptide that activates GLP-1, GIP, glucagon, amylin, and calcitonin receptors. It is more accurate to call it a candidate described by a researcher as a Volari Therapeutics asset; some authors disclosed current Lilly research support, without establishing support for this specific study.
Does the quintuple agonist have a name?
The candidate discussed in the ADA 2026 abstract is VRX-0075. A related Volari candidate, VRX-0136, has also been mentioned publicly. “Quintuple agonist” does not identify one unique molecule; the separate GLP-1/GIP-lanifibranor approach uses a different combination of five targets.
Is 2839-LB the drug name?
No. 2839-LB is the late-breaking abstract number assigned to the ADA 2026 presentation.
Is VRX-0075 approved?
No. VRX-0075 is preclinical and has no approved medical use.
Has VRX-0075 been tested in humans?
As of the November 8, 2026 review, the public sources located for this article describe preclinical research and do not establish a registered human trial or published human results for VRX-0075. This is a dated evidence review, not proof that no unreported development work exists.
What receptors does VRX-0075 target?
It is designed to activate the GLP-1, GIP, glucagon, amylin, and calcitonin receptors.
Is VRX-0075 better than retatrutide?
That is unknown. VRX-0075 produced greater weight loss than retatrutide in an obese-rat study at the same molar dose. Retatrutide has extensive human clinical data; VRX-0075 does not.
Why add amylin to a retatrutide-like mechanism?
Amylin can reduce meal size and promote satiation through pathways that partly complement GLP-1 signaling. The aim is to add another satiety mechanism without losing the metabolic effects of GLP-1, GIP, and glucagon activity.
Why target the calcitonin receptor?
Calcitonin and amylin pharmacology overlap. The calcitonin receptor can combine with RAMP proteins to form amylin receptor subtypes, and broader activation of this receptor family may affect appetite and body weight. The clinical value and trade-offs remain under study.
Does five receptors mean five times the effect?
No. Effects are not additive in a simple arithmetic sense. Relative potency, exposure, receptor distribution, signaling, and tolerability determine the overall outcome.
Could VRX-0075 be dosed weekly?
The rat pharmacokinetic data led the authors to suggest weekly human dosing may be feasible. Human studies are required to confirm that projection.
What side effects could occur?
No human side-effect profile exists. Based on the targeted pathways, gastrointestinal effects, excessive appetite suppression, glucose changes, heart-rate effects, and treatment discontinuation would be important to monitor, but candidate-specific risks cannot be predicted reliably before trials.
Does VRX-0075 preserve muscle?
No public evidence establishes lean-mass or muscle preservation. The ADA abstract did not report body-composition findings.
When will human trials begin?
No confirmed public start date was identified. Development timelines remain speculative until a trial is registered or a sponsor makes an official announcement.
Could quintuple agonists be the future of obesity drugs?
They may become part of the future, but receptor count alone will not decide success. The winning therapies will need to balance efficacy, safety, tolerability, convenience, durability, body composition, and access.
Final Perspective
VRX-0075 is one of the most ambitious metabolic peptide designs disclosed to date. By combining GLP-1, GIP, glucagon, amylin, and calcitonin receptor activity, it attempts to unite a retatrutide-like metabolic core with cagrilintide-like satiety pharmacology.
The early signal is worth watching: greater weight loss than retatrutide in obese rats at the same molar dose, receptor potency aligned with two prominent comparators, and a long-acting preclinical pharmacokinetic profile.
The caveat is equally important. VRX-0075 has not demonstrated safety, tolerability, or efficacy in humans. It should not be described as clinically superior to retatrutide, and a researcher described it as a Volari Therapeutics candidate, while some authors disclosed current Lilly research support. Neither establishes that Lilly funded this specific study or owns the candidate.
That correction does not make the story less interesting. It makes it more useful.
Obesity-drug development is moving from single-pathway appetite control toward deliberately balanced networks of metabolic and satiety signals. Whether five receptors prove better than three will depend on much more than a headline number. Human biology will decide whether VRX-0075 becomes a drug, a platform, or an instructive preclinical experiment.